Xarelto Dangerous After TAVR, Halted Trial Suggests

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

Xarelto Dangerous After TAVR, Halted Trial Suggests

Posted: 10/09/2018
Author:
Crtonline.org
News 2018 News Articles

Excess in thrombotic events and death vs. DAPT in GALILEO trial

The GALILEO trial of rivaroxaban (Xarelto) therapy after transcatheter aortic valve replacement (TAVR) has been stopped early after a preliminary analysis suggested harm, Bayer announced.
1-3 of 4074 results
1 2 3 4 5 Next »

Higher Overall Bleeds With CABG, but Greater Post-Discharge Risk for PCI in LMCAD Patients – EXCEL Analysis

Dec 02, 2024 by
Natalie Morrison, CRTonline.org

Left main coronary artery disease patients undergoing coronary artery bypass grafting in the EXCEL trial have higher 5-year major bleed rates than those on percutaneous coronary intervention (PCI), but PCI carry a greater risk of post-discharge bleeding.

Exercise Rehabilitation Should Become ‘Third Pillar’ in Stable Angina Treatment, Experts Urge

Dec 02, 2024 by
Natalie Morrison, CRTonline.org

Lifestyle interventions, including exercise-based cardiac rehabilitation (ExCR), should become the “third central pillar” in the treatment of stable angina, researchers have urged, following a review of Dutch public health insurance and studies in the field.

Experts Question Review Omission of Coronary Sinus Reducer for Angina Treatment

Dec 02, 2024 by
Will Chu, CRTonline.org

A recent letter published in the Journal of the American College of Cardiology calls for greater recognition of the Coronary Sinus Reducer (CSR) as an innovative therapy for patients with refractory angina.

1-3 of 4074 results
1 2 3 4 5 Next »

Most Viewed Pages

Higher Overall Bleeds With CABG, but Greater Post-Discharge Risk for PCI in LMCAD Patients – EXCEL Analysis

Exercise Rehabilitation Should Become ‘Third Pillar’ in Stable Angina Treatment, Experts Urge

Experts Question Review Omission of Coronary Sinus Reducer for Angina Treatment

Encouraging IVL Outcomes in ISR: NCDR Analysis

SAVR Using a Supra-Annular Self-Expanding Bioprothesis

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

Xarelto Dangerous After TAVR, Halted Trial Suggests

Excess in thrombotic events and death vs. DAPT in GALILEO trial

Higher Overall Bleeds With CABG, but Greater Post-Discharge Risk for PCI in LMCAD Patients – EXCEL Analysis

Exercise Rehabilitation Should Become ‘Third Pillar’ in Stable Angina Treatment, Experts Urge

Experts Question Review Omission of Coronary Sinus Reducer for Angina Treatment

Most Viewed Pages

Explore the Site

Stay Connected